Targeting IL-17 and TH17 cells in chronic inflammation
The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. Moreover, the demonstration that IL-17 and T(H)17 cells contribute to local and systemic aspects of disease pathogenesis, as well as the finding that the IL-17-T(H)17 cell pathway is regulated by IL-23, prompted the identification of inhibitors. These inhibitors include biotechnology products that target IL-23 as well as the leading member of the IL-17 family, IL-17A, and one of its receptors, IL-17 receptor A. Several clinical trials of these inhibitors are underway, and positive results have been obtained in psoriasis, rheumatoid arthritis and ankylosing spondylitis. This Review focuses on the current knowledge of the IL-17-T(H)17 cell pathway to better understand the positive as well as potential negative consequences of targeting them.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abs against IL-17/IL-17RA are in clinical trials for other autoimmune conditions [55].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [55]
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Research works printed but not linked: 1
- Baeten, D. et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 62, Abstract L3847 (2010).
Cited by
Items 401–500 of 1,000
Araujo, L. M. M., Fert, I., Jouhault, Q., Labroquère, K., Andrieu, M., Chiocchia, G., & Bréban, M. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38737 · Cited by 44
“In recent years, data have accumulated to show the crucial roles of Treg and Th17 cells in the development and/or regulation of numerous inflammatory/autoimmunity disorders (25-29).”
Discovery of biaryl carboxylamides as potent RORγ inverse agonists
Chao, J., Enyedy, I. J., van Vloten, K., Marcotte, D. J., Guertin, K. R., Hutchings, R. H., Powell, N. A., Jones, H., Bohnert, T., Peng, C., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.026 · Cited by 46
SINGH, S. P., Zhang, H. H., Tsang, H., Gardina, P. J., Myers, T. G., Nagarajan, V., Lee, C. H., & Farber, J. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401093 · Cited by 47
In Search of Magic Bullets: The Golden Age of Immunotherapeutics
O’Shea, J. J., Kanno, Y., & Chan, A. C. (2014) · Cell · doi:10.1016/j.cell.2014.03.010 · Cited by 42
Inhibition of IL-17 as a Pharmacological Approach for IBD
Fitzpatrick, L. R. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.821118 · Cited by 46
“IL-17E (IL-25), which binds to the IL-17B receptor (IL-17RB), has been reported to decrease inflammatory responses and plays a protective role in CD patients [1, 14, 45].”
BackgroundAbuHilal, M., Walsh, S. R., & Shear, N. H. (2016) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475416651605 · Cited by 46
CCAAT/Enhancer-binding protein β promotes pathogenesis of EAE
Simpson-Abelson, M. R., Hernández-Mir, G., Childs, E. E., Cruz, J. A., Poholek, A. C., Chattopadhyay, A., Gaffen, S. L., & McGeachy, M. J. (2017) · Cytokine · doi:10.1016/j.cyto.2017.01.005 · Cited by 56
Zeng, C., Chen, L., Chen, B., Cai, Y., Li, P., Yan, L., & Zeng, D. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy137 · Cited by 44
Lee, S., Kwon, J. Y., Moon, J., Choi, J., Jhun, J., Jung, K., Cho, K.-H., Darlami, O., Lee, H. H., Jung, E. S., et al. (2020) · Immune Network · doi:10.4110/in.2020.20.e16 · Cited by 45
“in excessive and chronic inflammatory response (25).”
Lv, Z., Guo, M. Z., Zhao, X., Shao, Y., Zhang, W., & Li, C. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100047 · Cited by 46
Krstić, J., Obradović, H., Jauković, A., Djordjević, I. O., Trivanović, D. I., Кукољ, Т., Mojsilović, S. B., Ilić, V. L., Santibanez, J. F., & Bugarski, D. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.11.025 · Cited by 44
“Although IL-17 is present in damaged or inflamed tissues and uPA recently has been implicated in migration and tropism to tumor microenvironment [13–15], the capacity of IL-17 to induce peripheral blood MSC (PB-MSC) migration and endothelium transmigration, as well as the involvement of uPA in these processes, was not…”
BackgroundSun, X., Gu, L., Deng, W.-S., & Xu, Q. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.2062 · Cited by 44
The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney
Ramani, K., Garg, A. V., Jawale, C. V., Conti, H. R., Whibley, N., Jackson, E. K., Shiva, S. S., Horne, W., Kolls, J. K., Gaffen, S. L., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005952 · Cited by 43
Self-citationDistinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases
Akiyama, S., & Sakuraba, A. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100104 · Cited by 47
“Several experimental animal models [11–13] demonstrated that IL-17 and TH17 cells play important roles in the pathologies of inflammatory bowel disease (IBD), psoriasis, and rheumatic diseases, suggesting that IL-17 can be a potential therapeutic target [2].”
BackgroundPrecision medicine in inflammatory bowel disease
Zeng, Z., Jiang, M., Li, X., Yuan, J., & Zhang, H. (2023) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbad033 · Cited by 47
“It is responsible for conferring pathogenicity to Th17 and pr oducing pr o-inflammatory cytokines including interleukin-17A ( IL-17A ) , interleukin-17F ( IL-17F ) , interleukin-22 ( IL-22 ) , TNF, C-C c hemokine r eceptor type 6 ( CCR6 ) , c hemokine ligand 20 ( CCL20 ) , and others [ 19 ].”
BackgroundTargeting persistently activated inflammatory microenvironment to promote chronic wound healing
Dai, Y., & Chen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708358 · Cited by 47
Aravindhan, V., & Haridoss, M. (2016) · Journal of Diabetes Research · doi:10.1155/2016/6264149 · Cited by 48
“Recently, several novel T cell cytokines like IL-33 [68], IL-17 [69], and IL-9 [70] have been described.”
BackgroundPotent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design
Narjes, F., Xue, Y., von Berg, S., Malmberg, J., Llinàs, A., Olsson, R. I., Jirholt, J., Grindebacke, H., Leffler, A., Hossain, N., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00783 · Cited by 44
Omidian, Z., Ahmed, R., Giwa, A., Donner, T. W., & Hamad, A. R. A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.09.001 · Cited by 45
“In patients with RA, secukinumab induced an ACR20 (American College of Rheumatology standard scale to measure the amount of improvement in RA in designated joints after treatment) response rate of 46% when compared to the 20% using placebo treatment in their Phase III clinical trial [76], also see Table 1.”
MethodSlc6a13 deficiency promotes Th17 responses during intestinal bacterial infection
Ren, W., Liao, Y., Ding, X., Jiang, Y., Yan, J., Xia, Y., Tan, B., Lin, Z., Duan, J., Jia, X., et al. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0111-7 · Cited by 45
Meijer, F. A., Doveston, R. G., de Vries, R. M. J. M., Vos, G. M., Vos, A. A. A., Leysen, S., Scheepstra, M., Ottmann, C., Milroy, L. ‐., & Brunsveld, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01372 · Cited by 49
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies
Cozzi, G., Scagnellato, L., Lorenzin, M., Savarino, E. V., Zingone, F., Ometto, F., Favero, M., Doria, A., Vavricka, S. R., & Ramonda, R. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00984-8 · Cited by 47
IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases
Li, H., & Tsokos, G. C. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08823-4 · Cited by 48
“After the establishment of pathogenic role of IL-23/IL-17 axis in different autoimmune and inflammatory diseases [9, 38], diligent work by many groups of researchers, clinicians, and industry colleagues has opened a new era for treatment opportunities for people who suffer from inflammatory rheumatic diseases.”
BackgroundInfluentialSignaling pathways in colorectal cancer: implications for the target therapies
Song, Y., Chen, M., Wei, Y., Ma, X., & Shi, H. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00178-y · Cited by 46
“IL17 stimulates the production of IL6, an inflammatory cytokine, and IL8, a chemokine ligand for CXCR2, which mediates neutrophil recruitment to tissues [110].”
BackgroundZhang, W., Zhang, X., Sheng, A., Weng, C., Zhu, T., Zhao, W., & Li, C. (2015) · Mediators of Inflammation · doi:10.1155/2015/258168 · Cited by 42
The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen
Correia, I., Sung, J. J., Burton, R. E., Jakob, C. G., Carragher, B. O., Ghayur, T., & Radziejewski, C. H. (2013) · mAbs · doi:10.4161/mabs.24258 · Cited by 45
Ulges, A., Witsch, E., Pramanik, G. K., Klein, M., Birkner, K., Bühler, U., Wasser, B., Luessi, F., Stergiou, N., Dietzen, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523869113 · Cited by 46
Cornez, I., Yajnanarayana, S. P., Wolf, A. M., & Wolf, D. G. F. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.035 · Cited by 45
The aggravation of arthritis by periodontitis is dependent of IL ‐17 receptor A activation
de Aquino, S. G., Talbot, J., Sônego, F., Turato, W. M., Grespan, R., Ávila-Campos, M. J., Cunha, F. Q., & Cirelli, J. A. (2017) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.12743 · Cited by 43
Nanjappa, S. G., McDermott, A. J., Fites, J. S., Galles, K., Wüthrich, M., Deepe, G. S., & Klein, B. S. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006356 · Cited by 45
Stabile, L. P., Farooqui, M., Kanterewicz, B. I., Abberbock, S. R., Kurland, B. F., Diergaarde, B. B., & Siegfried, J. M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.126 · Cited by 44
“Although the mouse with the largest tumor had the highest IL-6 value, overall total tumor burden did not correlate with that of the mice with more than 500 pg/mL IL-6.”
BackgroundInfluentialTerrades-García, N., & Cid, M. C. (2018) · Rheumatology · doi:10.1093/rheumatology/kex423 · Cited by 54
Cytokines and Their Genetic Polymorphisms Related to Periodontal Disease
Kozak, M., Dąbrowska‐Żamojcin, E., Mazurek−Mochol, M., & Pawlik, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124045 · Cited by 45
Maravitsa, P., Αδαμοπούλου, Μ., Pistiki, A. C., Netea, M. G., Louis, K., & Giamarellos‐Bourboulis, E. J. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.08.002 · Cited by 44
Hashiguchi, Y., Yabe, R., Chung, S.-H., Murayama, M. A., Yoshida, K., Matsuo, K., Kubo, S., Saijo, S., Nakamura, Y., Matsue, H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701157 · Cited by 42
“matory diseases such as psoriasis, psoriatic arthritis, and ankylosing sclerosis in humans (45, 46).”
BackgroundHuang, T., Gao, Z., Zhang, Y., Fan, K.-Q., Wang, F., Li, Y., Zhong, J.-Y., Fan, H., Cao, Q., Zhou, J., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180210 · Cited by 42
“Current evidence has indicated that the IL-23–IL-17 axis is crucial in the pathogenesis of psoriasis (Miossec and Kolls, 2012; Teng et al., 2015).”
BackgroundChaudhary, S. K., Singh, S. K., Kumari, P., Kanwal, S., Soman, S. P., Choudhury, S., & Garg, S. K. (2019) · Veterinary Dermatology · doi:10.1111/vde.12762 · Cited by 44
A Precision Medicine Approach to SARS-CoV-2 Pandemic Management
Crisci, C. D., Ardusso, L., Mossuz, A., & Müller, L. (2020) · Current Treatment Options in Allergy · doi:10.1007/s40521-020-00258-8 · Cited by 42
“Th17 cells are helper T cells differentiated from Th0 cells mainly stimulated by IL-6 and IL-23 [33] .”
BackgroundAilioaie, L. M., & Litscher, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186565 · Cited by 46
Therapeutic potency of curcumin for allergic diseases: A focus on immunomodulatory actions
Haftcheshmeh, S. M., Mirhafez, S. R., Abedi, M., Heydarlou, H., Shakeri, A., Mohammadi, A., & Sahebkar, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113646 · Cited by 40
Establishing a Role for Interleukin-17 in Atopic Dermatitis-Related Skin Inflammation
Tan, Q., Yang, H., Liu, E., & Wang, H. (2017) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475417697651 · Cited by 43
“In addition to cytokines produced by Th1 and Th2 cells, interleukin (IL)–17 has recently attracted attention because of its proinflammatory properties.(2) IL-17 production results in the upregulation of numerous inflammation-related genes in target cells, such as keratinocytes and fibroblasts.”
BackgroundLi, C., Zhang, J., Wang, W., Wang, H., Zhang, Y., & Zhang, Z. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.001 · Cited by 41
Resolvin E1 Regulates Th17 Function and T Cell Activation
Öner, F., Álvarez, C., Yaghmoor, W., Stephens, D. N., Hastürk, H., Fıratlı, E., & Kantarcı, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637983 · Cited by 42
Zhang, X., Zhang, X., Qiu, C., Shen, H., Zhang, H., He, Z., Song, Z., & Zhou, W. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ma0521-742rrr · Cited by 44
Old and New Players of Inflammation and Their Relationship With Cancer Development
Chavez-Dominguez, R., Perez-Medina, M., Aguilar‐Cázares, D., Galicia-Velasco, M., Meneses-Flores, M., Islas-Vázquez, L., Camarena, Á., & López-González, J. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722999 · Cited by 43
“Th17 cells are responsible for granulopoiesis and recruitment of neutrophils and macrophages in the injured zone; thus, they have been implicated in perpetuating chronic processes, such as psoriasis, Crohn’s disease, vasculitis, atherosclerosis, and asthma, among others (91).”
BackgroundImmunology of Diseases of the Oral Cavity
Challacombe, S., Shirlaw, P., & Thornhill, M. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00102-6 · Cited by 46
Zhang, C., Yan, K., Diao, Q., Guo, Q., Jin, H., Yang, S., Chen, X., Lei, T., Wu, J., Yu, H., et al. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.01.005 · Cited by 41
CXCL3: A key player in tumor microenvironment and inflammatory diseases
Bao, Y., Tong, C., & Xiong, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122691 · Cited by 46
Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
Yan, M., Man, S., Ma, L., Guo, L., Huang, L., & Gao, W. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0315 · Cited by 44
Wang, G., Wang, J., Ma, H., Ansari, G. A. S., & Khan, M. F. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.08.020 · Cited by 39
“In recent years, free radical-mediated reactions as the potential mechanism in the pathogenesis of ADs have drawn increasing attention (Khan et al., 2001; Kurien and Scofield, 2008; Oates, 2010).”
InfluentialInterleukin-17 and type 17 helper T cells in cancer management and research
Housseau, F., Geis, A. L., Orberg, E. T., & Llosa, N. J. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s56529 · Cited by 43
“A Phase II clinical trial of therapies targeting IL-12/p40, common to IL-12 and IL-23, showed encouraging results in the treatment of psoriasis, but rendered individuals with an increased susceptibility to infections.(84) A Phase III randomized controlled trial that used the fully human IL-12/IL-23 mAb (briakinumab) i…”
BackgroundResultMaggio, R., Viscomi, C., Andreozzi, P., d’Ettorre, G., Viscogliosi, G., Barbaro, B., Gori, M., Vullo, V., & Balsano, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112346 · Cited by 39
“Confirming several studies [36–38], we observed a remarkable higher frequency of Th17 cells in blood of CHC patients with respect to healthy individuals, and a slight increase in NAFLD/NASH subjects.”
ResultMorgan, M. E., Koelink, P. J., Zheng, B., den Brok, M. H. M. G. M., van de Kant, H. J. G., Verspaget, H. W., Folkerts, G., Adema, G. J., & Kraneveld, A. D. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.16 · Cited by 42
“accumulation of neutrophils.(9) Th17 cells are characterized by the master transcription factor, retinoic acid-related orphan receptor gt (RORgt) and the production of IL-17A, IL-17F, IL-22, IL-26, tumor necrosis factor a, and granulocyte macrophage colony-stimulating factor.”
BackgroundIbrahim, S., Girault, A., Ohresser, M. C. P., Lereclus, E., Paintaud, G., Lecomte, T., & Raoul, W. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.003 · Cited by 39
“A canonical source of IL-17A is a lineage of T cells known as CD4þ T helper Th17 cells.(17) Transforming growth factor-b, IL-6, IL-21, and other factors usually released in the tumor microenvironment are responsible for the induction of Th17 differentiation and IL-23 contributes to sustain the Th17 phenotype.”
BackgroundKiltz, U., Sfikakis, P. P., Gaffney, K., Sator, P.-G., von Kiedrowski, R., Bounas, A., Gullick, N., Conrad, C., Rigopoulos, D., Lespessailles, É., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01352-8 · Cited by 38
Interleukin-17 promotes nitric oxide-dependent expression of PD-L1 in mesenchymal stem cells
Wang, S., Wang, G., Zhang, L., Li, F., Liu, K., Wang, Y., Shi, Y., & Cao, K. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00431-1 · Cited by 44
Rodríguez‐Cerdeira, C., González-Cespón, J. L., Martínez-Herrera, E. O., Carnero-Gregorio, M., López-Bárcenas, A., Sergeev, A. Y., & Saunte, D. M. L. (2021) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.20.06580-3 · Cited by 38
Zhang, D., Li, B., & Zhao, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.667763 · Cited by 46
“IL-17 is considered as a marker of Th17 cell subsets (Miossec and Kolls, 2012).”
BackgroundSun, Y., Wang, Q., Wang, Y., Ren, W., Cao, Y., Li, J., Zhou, X., Fu, W., & Yang, J. H. (2021) · Protein & Cell · doi:10.1007/s13238-021-00835-w · Cited by 38
“IL-17A and IL17F have been established as the central pro-inflammatory cytokines in colitis (Iwakura et al., 2011; Miossec and Kolls, 2012), though a controversy regarding IL-17A is noted (Ito et al., 2008; Yang et al., 2008; Tang et al., 2018).”
BackgroundOlveira, A., Augustín, S., Benlloch, S., Ampuero, J., Suárez‐Pérez, J. A., Armesto, S., Vilarrasa, E., Belinchón, I., Herranz, P., Crespo, J., et al. (2023) · Life · doi:10.3390/life13020419 · Cited by 44
“IL-17 stimulates the production of numerous chemokines, such as IL-8, chemokine (C-X-C motif) ligand (CXCL) 1, CXCL2, CXCL5, chemokine (C-C motif) ligand (CCL) 2, CCL7, CCL20; cytokines, such as TNF, IL-6, IL-1β, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF);…”
BackgroundBurn Wound γδ T-Cells Support a Th2 and Th17 Immune Response
Rani, M., Zhang, Q., & Schwacha, M. G. (2013) · Journal of Burn Care & Research · doi:10.1097/01.bcr.0000440705.91099.cc · Cited by 43
Bonaventura, P., Courbon, G., Lamboux, A., Lavocat, F., Marotte, H., Albarède, F., & Miossec, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-02611-5 · Cited by 38
Self-citationGastrointestinal involvement attenuates COVID-19 severity and mortalityPreprint
Livanos, A. E., Jha, D., Cossarini, F., Gonzalez-Reiche, A. S., Tokuyama, M. A., Aydillo, T., Parigi, T. L., Ramos, I., Dunleavy, K. A., Lee, B. H., et al. (2020) · medRxiv · doi:10.1101/2020.09.07.20187666 · Cited by 44
Targeting regulatory T cells for cardiovascular diseases
Wang, X., Zhou, H., Liu, Q., Cheng, P., Zhao, T., Yang, T., Zhao, Y., Sha, W., Zhao, Y., & Qu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126761 · Cited by 41
“Naive CD4 T cells differentiate into different subsets of cells according to different cytokine environments, including 1 helper T (Th1)cells, Th2 cells, Th17 cells (61), and Tregs, which share the exact origin but exhibit opposite effects (62).”
BackgroundSohn, R. E., & Jenei‐Lanzl, Z. (2023) · NeuroImmunoModulation · doi:10.1159/000531798 · Cited by 38
“While Th1 cells secrete both pro-and anti-in fl ammatory cytokines, Th2 cells release anti-in fl ammatory cytokines, and Th17 cells mainly release the pro-in fl ammatory-acting IL-17 [66].”
BackgroundNanomedicine-based immunotherapy for tissue regeneration
Li, S., Lü, L., Xiong, Y., & Xiao, J. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf015 · Cited by 42
Suzuki, T., Hirakawa, S., Shimauchi, T., Ito, T., Sakabe, J., Detmar, M. J., & TOKURA, Y. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.12.013 · Cited by 37
“This cytokine network has been proven by the therapeutic effectiveness of cytokine blocking biologics [4], including antibody therapies to TNF-a, IL-23/IL-12p40, and IL-17 or its receptors.”
BackgroundTh17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect
Jimeno, R., Leceta, J., Garín, M., Ortiz, A. M., Mellado, M., Rodríguez-Frade, J. M., Martínez, C., Pérez-García, S., Gomariz, R. P., & Juarranz, Y. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0714-327r · Cited by 37
“IL-21 was also identified as an autocrine cytokine enhancing Th17 cell differentiation and proliferation [35].”
BackgroundResultIL ‐17A‐producing CD 30+ Vδ1 T cells drive inflammation‐induced cancer progression
Kimura, Y., Nagai, N., Tsunekawa, N., Sato‐Matsushita, M., Yoshimoto, T., Cua, D. J., Iwakura, Y., Yagita∥, H., Okada, F., Tahara, H., et al. (2016) · Cancer Science · doi:10.1111/cas.13005 · Cited by 41
Ecoeur, F., Weiss, J., Kaupmann, K., Hintermann, S., Orain, D., & Guntermann, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00577 · Cited by 41
Rebalancing the unbalanced aged immune system – A special focus on zinc
Baarz, B. R., & Rink, L. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101541 · Cited by 41
Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases
Yamagata, T., Skepner, J. E., & Yang, J. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0362-x · Cited by 40
Rheumatoid arthritis patients exhibit impaired Candida albicans-specific Th17 responses
Bishu, S., Su, E. W., Wilkerson, E. R., Reckley, K. A., Jones, D. M., McGeachy, M. J., Gaffen, S. L., & Levesque, M. C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4480 · Cited by 38
“Hence, agents that inhibit the Th17 pathway at multiple points, including inhibitors of JAK kinases, IL-23, IL-17A and IL-17RA, are currently being used or evaluated in RA and other autoimmune conditions [9,28].”
BackgroundCIKS/DDX3X Interaction Controls the Stability of the Zc3h12a mRNA Induced by IL-17
Somma, D., Mastrovito, P., Grieco, M., Lavorgna, A., Pignalosa, A., Formisano, L., Salzano, A. M., Scaloni, A., Pacifico, F., Siebenlist, U., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401589 · Cited by 36
Context-Dependent Regulation of Type17 Immunity by Microbiota at the Intestinal Barrier
Akuzum, B., & Lee, J. (2022) · Immune Network · doi:10.4110/in.2022.22.e46 · Cited by 37
“On the other hand, type17 immune cells are also important drivers of a variety of chronic inflammatory disorders, including autoimmune diseases and IBD, and have been linked to inflammation associated with epithelial carcinogenesis (20-22) (Fig.”
BackgroundThe Role of IL-17 in the Pathogenesis of Oral Squamous Cell Carcinoma
Ladjevac, N., Milovanović, M., Jevtović, A., Arsenijević, D., Stojanović, B., Stojanovic, M. D., Stojanović, B., Arsenijević, N., Arsenijević, A., & Milovanović, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129874 · Cited by 39
Inflammation accelerating intestinal fibrosis: from mechanism to clinic
Xin, S., Liu, X., He, C., Gao, H., Wang, B., Hua, R., Gao, L., Shang, H., Sun, F., & Xu, J. (2024) · European journal of medical research · doi:10.1186/s40001-024-01932-2 · Cited by 41
“IL-12 also effectively promotes Th2 production with IL-4 as well IL-5/13 [17].”
BackgroundBrodalumab: A new way to inhibit IL ‐17 in psoriasis
Facheris, P., Valenti, M., Pavia, G., Guanziroli, E., Narcisi, A., Borroni, R. G., & Costanzo, A. (2020) · Dermatologic Therapy · doi:10.1111/dth.13403 · Cited by 39
“Th17 lymphocytes produce several cytokines such as IL-17A, IL-17F, IL-21, IL-22, and TNF-α.7,8 The definition of psoriasis as an immune disease heralded the use of systemic biological agents for the treatment of this condition.”
BackgroundGastroenterological safety of IL-17 inhibitors: a systematic literature review
Caron, B., Jouzeau, J., Miossec, P., Petitpain, N., Gillet, P., Netter, P., & Peyrin‐Biroulet, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1960981 · Cited by 36
“IL-17A and IL-17 F are the key cytokines produced by T helper 17 (TH17) cells [2].”
BackgroundSelf-citationHyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 37
“Inhibiting the expression of PD-1 in tumors leads to increased levels of IL-6 and IL-17 in the peripheral blood; because the main function of IL-6 and IL-17 is to promote neutrophil-mediated inflammation, this may weaken the anti-tumor immune response (Fielding et al., 2008; Miossec and Kolls, 2012).”
BackgroundLymphocytes: Versatile Participants in Acute Kidney Injury and Progression to Chronic Kidney Disease
Cao, C., Yao, Y., & Zeng, R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.729084 · Cited by 37
de Oliveira, C. B., Vasconcellos, C., Sakai-Valente, N. Y., Sotto, M. N., Guedes, F., Belda, W., Sousa, M. G. T., Benard, G., & Criado, P. R. (2015) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652015000100008 · Cited by 36
Ndongo-Thiam, N., & Miossec, P. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207110 · Cited by 37
Self-citationSaitō, M., Otsuka, K., Ushio, A., Yamada, A., Arakaki, R., Kudo, Y., & Ishimaru, N. (2017) · Current Rheumatology Reviews · doi:10.2174/1573397113666170125122858 · Cited by 41
“Th17 cells are characterized by production of the proinflammatory cytokine, IL-17 and have been implicated in various immune responses, such as autoimmunity [40-44].”
BackgroundTherapeutic Potential of IL‐17‐Mediated Signaling Pathway in Autoimmune Liver Diseases
Zhang, H., Bernuzzi, F., Lleò, A., Ma, X., & Invernizzi, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/436450 · Cited by 38
“Presently, the clinical trials of these two antibodies are still in process [116].”
BackgroundInnate and ozone-induced airway hyperresponsiveness in obese mice: role of TNF-α
Williams, A. S., Mathews, J. A., Kasahara, D. I., Wurmbrand, A. P., Chen, L., & Shore, S. A. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00393.2014 · Cited by 35
“4D), coupled with the important role for IL-17A in neutrophil recruitment (37), suggests that the reduction in BAL neutrophils in the Cpe/TNF- / vs.”
Poddubnyy, D., & Sieper, J. (2017) · Rheumatology · doi:10.1093/rheumatology/kex361 · Cited by 40
Fluoride Induces Autoimmune Orchitis Involved with Enhanced IL-17A Secretion in Mice Testis
Wu, P., Sun, Z., Lv, X., Pei, X., Manthari, R. K., & Wang, J. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b05789 · Cited by 35
Zheng, J., Chen, D., Xu, J., Ding, X., Wu, Y., Shen, H. C., & Tan, X. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128229 · Cited by 36
Fennen, M., Weinhage, T., Kracke, V., Intemann, J., Varga, G., Wehmeyer, C., Foell, D., Korb‐Pap, A., Pap, T., & Dankbar, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-93599-6 · Cited by 36
Sun, N., Xie, Q., Dang, Y., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02178 · Cited by 39
Cytokines and microRNAs in SARS-CoV-2: What do we know?
Rarani, F. Z., Rashidi, B., Abadi, M. H. J. N., Hamblin, M. R., Hashemian, S. M. R., & Mirzaei, H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.017 · Cited by 35
Saeed, M. A., Ng, G. Z., Däbritz, J., Wagner, J., Judd, L. M., Han, J.-X., Dhar, P., Kirkwood, C. D., & SUTTON, P. R. N. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001045 · Cited by 37
Narjes, F., Llinàs, A., von Berg, S., Jirholt, J., Lever, S. R., Pehrson, R., Collins, M., Malmberg, A., Svanberg, P., Xue, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01197 · Cited by 35
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Zhou, Z.-H., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 37
Zhang, R., Chen, S., Chen, L., Ye, L., Jiang, Y., Peng, H., Guo, Z., Li, M., Jiang, X., Guo, P., et al. (2022) · Particle and Fibre Toxicology · doi:10.1186/s12989-022-00483-w · Cited by 37
“It orchestras with the other pro-inflammatory cytokines such as IL-6 and TNF-α to amplify the inflammation signaling induced by different xenobiotics [30, 31].”
BackgroundMohamed, Y. T., Salama, A., Rabie, M. A., & Fattah, M. A. A. E. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109571 · Cited by 37
O’Shea, J. J., & Jones, R. G. (2013) · Nature · doi:10.1038/nature11959 · Cited by 36
Effect of interleukin-17 on gene expression profile of fibroblasts from Crohn's disease patients
Kerami, Z., Duijvis, N. W., Vogels, E. W. M., van Dooren, F. H., Moerland, P. D., & Velde, A. A. T. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.02.009 · Cited by 37
Metadata
- Authors
- Miossec, P., & Kolls, J. K.
- Affiliations
- Lyon 1 Université (FR)
- University of Pittsburgh (US)
- Corresponding author
- Miossec, Pierre
- Kolls, Jay K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 763-776
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2022917731
- Cited by
- 1,414
- References
- 169
- Citations by year
- 2026: 74 · 2025: 104 · 2024: 137 · 2023: 101 · 2022: 121 · 2021: 129 · 2020: 97 · 2019: 91 · 2018: 67 · 2017: 114 · 2016: 100 · 2015: 109 · 2014: 97 · 2013: 72 · 2012: 1
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Universitaire de France
- Institut Mérieux
- National Heart, Lung, and Blood Institute (R37HL079142)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- IL-17, Th17 cells, IL-17 inhibitors, IL-23, IL-17 receptor A, psoriasis, rheumatoid arthritis, ankylosing spondylitis, chronic inflammation, autoimmunity, biologic therapy, IL-17A
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Drug Delivery Systems, Interleukin-17, Receptors, Interleukin-17, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.